LinkedIn Icon Register by September 22 to save £400
31 October – 2 November , 2017

London, UK

 

 

Speakers

Expand/Collapse

Magda Papadaki
Head, Manufacturing Innovation
The Association of the British Pharmaceutical Industry (ABPI)

Day One

Wednesday 1st November, 2017

16.00 | Investigating the Regulatory Perspective on Clinical Development, Manufacturing & Market Approval

Day Two

Thursday 2nd November, 2017

15.30 | Panel Discussion: How can Organisations Forge Mutually Beneficial Alliances in the Gene Therapy Field?

Alexis Cockroft
Regulatory Manager, Biopharm CMC Regulatory Affairs
GSK

Day One

Wednesday 1st November, 2017

15.30 | Registering a Cell-Based Gene Therapy Product - CMC Considerations

Diego Ardigo
Project Leader - Advanced Therapy Medicinal Product, Biologics, Corporate Drug Development, Research & Development
Chiesi

Day Two

Thursday 2nd November, 2017

10.00 | Multi-Stakeholder Panel on Executing Effective Pricing, Reimbursement & Market Access Approaches

Robert Baffi
EVP, Technical Operations
BioMarin

Day Two

Thursday 2nd November, 2017

12.00 | Improving the Scalability of Gene Therapy Manufacturing

Jean-Philippe Combal
CEO
Vivet Therapeutics

Day One

Wednesday 1st November, 2017

10.00 | Investigating Novel Vector Technology with the Promise of Enhancing the Efficacy of Gene Therapy

Emily Culme-Seymour
External Strategy Manager, Gene Therapy, Rare Diseases Unit
GSK

Day Two

Thursday 2nd November, 2017

15.30 | Panel Discussion: How can Organisations Forge Mutually Beneficial Alliances in the Gene Therapy Field?

Michela Gabaldo
Head, Alliance Management & Regulatory Affairs
TIGET

Day One

Wednesday 1st November, 2017

16.00 | Investigating the Regulatory Perspective on Clinical Development, Manufacturing & Market Approval

Day Two

Thursday 2nd November, 2017

15.30 | Panel Discussion: How can Organisations Forge Mutually Beneficial Alliances in the Gene Therapy Field?

Aniz Girach
CMO
NightstarX

Day One

Wednesday 1st November, 2017

11.30 | The Selection of Endpoints for Ophthalmology Gene Therapy Trials in the Rare Disease Space

William Green
Senior Research Consultant
York Health Economics Consortium

Day Two

Thursday 2nd November, 2017

10.00 | Multi-Stakeholder Panel on Executing Effective Pricing, Reimbursement & Market Access Approaches

Grace Hampson
Senior Economist
Office of Health Economics

Day Two

Thursday 2nd November, 2017

09.30 | Options for Managing Budget Impact of High Cost Gene Therapies

Reinout Hesselink
Consultant, Cell and Gene Therapy
Exmoor Pharma Consulting

Chris Hollowood
Chief Investment Officer
Syncona

Day Two

Thursday 2nd November, 2017

14.00 | Panel Discussion: How do Investors View the Gene Therapy Space?

Sven Kili
VP, Head of Cell & Gene Therapy Development
GSK

Day One

Wednesday 1st November, 2017

09.00 | Keynote Panel Discussion – The Future of Gene Therapies for Rare Disease

Day Two

Thursday 2nd November, 2017

10.00 | Multi-Stakeholder Panel on Executing Effective Pricing, Reimbursement & Market Access Approaches

08.30 | Keynote: Establishing Value for Gene Therapy Products by Implementing Effective Reimbursement Strategies

Hanspeter Rottensteiner
Associate Director, Gene Therapy
Shire

Day One

Wednesday 1st November, 2017

09.00 | Keynote Panel Discussion – The Future of Gene Therapies for Rare Disease

Day Two

Thursday 2nd November, 2017

11.00 | Optimising Vectorology, Process Development & Cross-Industry Standardisation

Adrien Lemoine
VP, Business Development & Operations
Orchard Therapeutics

Day Two

Thursday 2nd November, 2017

15.30 | Panel Discussion: How can Organisations Forge Mutually Beneficial Alliances in the Gene Therapy Field?

Gopalan Narayanan
VP, Disruptive Biologics
Voisin Consulting

Day One

Wednesday 1st November, 2017

16.00 | Investigating the Regulatory Perspective on Clinical Development, Manufacturing & Market Approval

Christiane Niederlaender
CAT Member, Senior Quality Assessor
UK Medicines and Healthcare Products Regulatory Agency (MHRA)

Day One

Wednesday 1st November, 2017

16.00 | Investigating the Regulatory Perspective on Clinical Development, Manufacturing & Market Approval

15.00 | MHRA Perspective on Gene Therapies for Rare Disorders

Samantha Parker
Chief Patient Affairs & Health Policies Officer
Lysogene

Day Two

Thursday 2nd November, 2017

15.00 | Uniting the Rare Disease Community Around Key Patient Affairs and Policy Objectives

Detlev Parow
Head, Department of Care Management Development
DAK

Day Two

Thursday 2nd November, 2017

10.00 | Multi-Stakeholder Panel on Executing Effective Pricing, Reimbursement & Market Access Approaches

09.00 | The Payer Perspective: Glybera Insights – What are the Key Takeaways?

Wim Scheele
Executive Director, Rare Disease Clinical Development & Operations
Pfizer

Day One

Wednesday 1st November, 2017

12.00 | Discussing how we can Define and Maintain Clinical Standards – Is Gene Therapy a Special Case?

09.00 | Keynote Panel Discussion – The Future of Gene Therapies for Rare Disease

Rafaele Tordjman
Independent Venture Capitalist, Independent Board Member
Obseva & WITH Association

Day Two

Thursday 2nd November, 2017

14.00 | Panel Discussion: How do Investors View the Gene Therapy Space?

Pamela Tranter
Head, Translational Research Group
UCL

Day Two

Thursday 2nd November, 2017

13.30 | Identifying Opportunities to Translate Gene Therapy in Academia & Key Factors to Address Using Case Study Examples

Sander van Deventer
Managing Partner/CSO
Forbion Capital Partners/uniQure

Day One

Wednesday 1st November, 2017

16.45 | Chair’s Closing Remarks

08.30 | Keynote: Investigating Critical Challenges in the Gene Therapy Field – Mapping out the Landscape & Discussing Future Strategies

08.20 | Chair’s Opening Remarks

Day Two

Thursday 2nd November, 2017

16.15 | Chair’s Closing Remarks

14.00 | Panel Discussion: How do Investors View the Gene Therapy Space?

08.20 | Chair’s Opening Remarks

Joseph Earley
Senior Scientist, Downstream Process Development
Allergan

Day Two

Thursday 2nd November, 2017

11.30 | Enhancing the Manufacturability of Gene Therapies

Ann Gorman
Director, Regulatory Science
Voisin Consulting

Pre Conference Workshops

Tuesday, 31st October, 2017

09.00 | Workshop A: Investigating the Unique Regulatory Landscape of the Gene Therapy Field